Royalty Pharma PLC (NASDAQ:RPRX) Receives Consensus Recommendation of “Buy” from Brokerages

Shares of Royalty Pharma PLC (NASDAQ:RPRX) have earned a consensus rating of “Buy” from the six analysts that are currently covering the firm, Marketbeat Ratings reports. Six equities research analysts have rated the stock with a buy rating. The average 1 year target price among analysts that have updated their coverage on the stock in the last year is $48.6667.

A number of brokerages have recently issued reports on RPRX. Leerink Partners set a $45.00 target price on Royalty Pharma in a research report on Thursday, December 11th. TD Cowen reissued a “buy” rating on shares of Royalty Pharma in a report on Friday, February 27th. Morgan Stanley restated an “overweight” rating and set a $61.00 price objective on shares of Royalty Pharma in a research note on Thursday, February 12th. Weiss Ratings upgraded Royalty Pharma from a “hold (c+)” rating to a “buy (b-)” rating in a report on Thursday, February 12th. Finally, The Goldman Sachs Group reiterated a “buy” rating on shares of Royalty Pharma in a research note on Thursday, February 12th.

Insiders Place Their Bets

In other Royalty Pharma news, CFO Terrance P. Coyne sold 114,954 shares of the firm’s stock in a transaction on Tuesday, February 3rd. The shares were sold at an average price of $42.84, for a total transaction of $4,924,629.36. Following the completion of the transaction, the chief financial officer directly owned 23,972 shares of the company’s stock, valued at $1,026,960.48. This trade represents a 82.74% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Marshall Urist sold 20,000 shares of the business’s stock in a transaction dated Friday, January 16th. The stock was sold at an average price of $39.52, for a total transaction of $790,400.00. Following the completion of the sale, the executive vice president directly owned 40,000 shares of the company’s stock, valued at $1,580,800. The trade was a 33.33% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 532,287 shares of company stock worth $22,215,917 over the last quarter. 18.90% of the stock is currently owned by insiders.

Institutional Trading of Royalty Pharma

Several hedge funds and other institutional investors have recently bought and sold shares of RPRX. Rockefeller Capital Management L.P. raised its stake in Royalty Pharma by 1,347.4% during the fourth quarter. Rockefeller Capital Management L.P. now owns 87,814 shares of the biopharmaceutical company’s stock valued at $3,393,000 after buying an additional 81,747 shares in the last quarter. World Investment Advisors increased its holdings in shares of Royalty Pharma by 21.1% in the 4th quarter. World Investment Advisors now owns 58,434 shares of the biopharmaceutical company’s stock valued at $2,258,000 after acquiring an additional 10,178 shares during the last quarter. Caitong International Asset Management Co. Ltd increased its holdings in shares of Royalty Pharma by 29.5% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 3,681 shares of the biopharmaceutical company’s stock valued at $142,000 after acquiring an additional 838 shares during the last quarter. Compound Planning Inc. raised its position in shares of Royalty Pharma by 21.7% during the 4th quarter. Compound Planning Inc. now owns 10,618 shares of the biopharmaceutical company’s stock valued at $410,000 after acquiring an additional 1,896 shares in the last quarter. Finally, Corient Private Wealth LLC raised its position in shares of Royalty Pharma by 26.8% during the 4th quarter. Corient Private Wealth LLC now owns 154,922 shares of the biopharmaceutical company’s stock valued at $5,986,000 after acquiring an additional 32,766 shares in the last quarter. 54.35% of the stock is owned by institutional investors.

Royalty Pharma Price Performance

RPRX opened at $47.97 on Friday. Royalty Pharma has a twelve month low of $29.66 and a twelve month high of $47.98. The firm has a market cap of $27.67 billion, a price-to-earnings ratio of 35.53 and a beta of 0.40. The company has a current ratio of 2.40, a quick ratio of 2.40 and a debt-to-equity ratio of 0.88. The company has a fifty day simple moving average of $44.73 and a 200 day simple moving average of $40.43.

Royalty Pharma (NASDAQ:RPRX) last issued its quarterly earnings data on Wednesday, February 11th. The biopharmaceutical company reported $1.46 EPS for the quarter, topping analysts’ consensus estimates of $1.33 by $0.13. The firm had revenue of $621.99 million for the quarter, compared to analyst estimates of $839.97 million. Royalty Pharma had a net margin of 32.38% and a return on equity of 28.21%. Equities research analysts expect that Royalty Pharma will post 4.49 EPS for the current fiscal year.

Royalty Pharma Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Tuesday, March 10th. Investors of record on Friday, February 20th were issued a $0.235 dividend. This is a boost from Royalty Pharma’s previous quarterly dividend of $0.22. This represents a $0.94 annualized dividend and a yield of 2.0%. The ex-dividend date of this dividend was Friday, February 20th. Royalty Pharma’s dividend payout ratio is currently 69.63%.

Royalty Pharma Company Profile

Royalty Pharma plc is a specialty finance company that acquires biopharmaceutical royalty interests and provides non-dilutive financing to drug developers and rights holders. The firm purchases future royalty streams, milestone-contingent payments and other revenue rights linked to approved and late-stage pharmaceutical and biotechnology products. By paying upfront consideration for these rights, Royalty Pharma seeks to generate long-term cash flows tied to the commercial performance of a diversified portfolio of medicines.

The company’s transaction structures include outright royalty purchases, structured financings and milestone arrangements tailored to the needs of innovator companies, academic institutions and investors.